Transgender men and women represent about 0.6-1.1%% of the general population.
Gender affirming hormone therapy (GAHT) helps ameliorate gender dysphoria and promote …

Transgender health research is undergoing rapid transformation with higher quality studies
becoming increasingly available. Yet, the state-of the science in many areas of transgender …

Objective The impact of gender-affirming hormone therapy (GAHT) on cardiovascular (CV)
health is still not entirely established. A systematic review was conducted to summarize the …

BACKGROUND Gender-affirming hormonal therapy consists of testosterone in transgender
men and estrogens and antiandrogens in transgender women. Research has concluded …

Testosterone is the main hormonal agent used for cross‐sex hormone therapy in female‐to‐
male transgender persons. Our aim was to systematically review the literature concerning …

Objectives: Gender-affirming hormone therapy (GHT) is utilized by people who are
transgender to align their secondary sex characteristics with their gender identity. Data …

Objective Accumulating evidence demonstrates that gender affirming hormone therapy
improves mental health outcomes in transgender persons. Data specific to the risks …

Context The effect of gender-affirming hormone therapy (HT) on erythropoiesis is an area of
priority in transgender health research. Objective To compare changes in hematologic …

The menopause transition and post-menopause period marks a time of dynamic
physiological and hormonal change. Cisgender women commonly experience vasomotor …